Воронина Т.А., Середенин С.Б. Перспективы поиска новых анксиолитиков. Проблемная статья // Эксперим. и клин. фармакология. - 2002. - т. 65 - № 5 - С. 4-17.
Селезнёва Н.Д., Гаврилова С.И., Колыхалов И.В и др. Клинико-генетические предикторы ответа на холинергическую и глутаматергическую терапию при болезни Альцгеймера // Психиатрия и психофармакотерапия. - 2001. - Т. 3. - № 2.
Baldessarini R.J., Tondo L., Strombom I.M. et al. Ecological studies of antidepressant treatment and suicidal risks // Harv. Rev. Psychiatry. - 2007. - Vol. 15. - Р. 133-145.
Baldwin D.S., Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder // Int. J. Neuropsychopharmacol. - 2005. - Vol. 8. - Р. 293-302.
Birks J.Cholinesterase inhibitors for Alzheimer's disease // Cochrane Database Syst. Rev. - 2006 - Jan 25;(1)
Danish University antidepressant group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study // J. affect Disord. - 1990. - Vol. 18. - Р. 89-299.
Fountoulakis K.N., Vieta E., Siamouli M. et al. Treatment of bipolar disorder: a complex treatment for a multi-facet disorder // Ann. Gen. Psychiatry. - 2007. - Vol. 6. - Р. 27
Green M.F., Braff D.L. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications // Biol. Psychiatry. - 2001. - Vol. 49. - Р. 374-84.
McEwen B.S., Olie J.P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine // Molecular. psychiatry - 2005 -N 10. - Р. 525-536.
Thaker G.K. Schizophrenia endophenotypes as treatment targets // Expert Opin Ther Targets. - 2007. - Vol. 11. - Р. 1189-1206.